KRAS and non-small cell lung carcinoma: Earlier studies have indicated that patients with NSCLC carrying KRAS mutations exhibit elevated levels of YAP expression, and YAP1 silencing can enhance response to trametinib in human lung adenocarcinoma cells (MOR/CPR) encoding KRAS G12C [91].